Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study.

Sara De Carolis, Amelia Ruffatti, Elisa Salvan, Teresa Del Ross, Maria Gerosa, Laura Andreoli, Aldo Maina, Jaume Alijotas-Reig, Arsene Mekinian, Maria Tiziana Bertero, Valentina Canti, Antonio Brucato, Katarina Bremme, Véronique Ramoni, Marta Mosca, Emma Di Poi, Paola Caramaschi, Mauro Galeazzi, Angela Tincani, Pier Luigi Meroni

Risultato della ricerca: Contributo in rivistaArticolo in rivista

83 Citazioni (Scopus)

Abstract

Previous thrombosis, diagnosis of systemic lupus erythematosus (SLE) and triple antiphospholipid (aPL) antibody positivity have recently been found to be independent factors associated to pregnancy failure during conventional therapy in women with antiphospholipid syndrome (APS). This study aimed to assess the effect of various treatment strategies on pregnancy outcomes in women with APS and the risk factors for pregnancy failure. One hundred ninety-six pregnancies of 156 patients diagnosed with APS were analysed: 118 (60.2%) of these had previous thrombosis, 81 (41.3%) were diagnosed with SLE, and 107 (54.6%) had triple aPL positivity. One hundred seventy-five (89.3%) were treated with conventional therapies (low-dose aspirin [LDA] or prophylactic doses of heparin + LDA or therapeutic doses of heparin + LDA), while 21 (10.7%) were prescribed other treatments in addition to conventional therapy. The pregnancies were classified into seven risk profiles depending on the patients' risk factors - thrombosis, SLE, and triple aPL positivity - and their single, double or triple combinations. It was possible to find significant difference in outcomes correlated to treatments only in the thrombosis plus triple aPL positivity subset, and logistic regression analysis showed that additional treatments were the only independent factor associated to a favourable pregnancy outcome (odds ratio=9.7, 95% confidence interval=1.1-88.9, p-value<0.05). On the basis of this retrospective study, we found that APS pregnant patients with thrombosis and triple aPL positivity treated with additional therapy had a significant higher live-birth rate with respect to those receiving conventional therapy alone.
Lingua originaleEnglish
pagine (da-a)727-735
Numero di pagine9
RivistaThrombosis and Haemostasis
Volume2014/112
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Antiphospholipid antibodies
  • antiphospholipid syndrome
  • pregnancy
  • risk factors
  • treatment

Fingerprint

Entra nei temi di ricerca di 'Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study.'. Insieme formano una fingerprint unica.

Cita questo